Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study

BACKGROUND: Disease assessment for recurrent glioblastoma (GBM) represents a challenge, especially with the use of antiangiogenic agents. Moreover, validated neuroradiological predictors of outcome are lacking. Recently, the concept of early tumor shrinkage (ETS) has been developed to better assess...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Brandes, Alba A., Finocchiaro, Gaetano, Zagonel, Vittorina, Reni, Michele, Fabi, Alessandra, Caserta, Claudia, Tosoni, Alicia, Eoli, Marica, Lombardi, Giuseppe, Clavarezza, Matteo, Paccapelo, Alexandro, Bartolini, Stefania, Cirillo, Luigi, Agati, Raffaele, Franceschi, Enrico
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Clinical Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5589683/
https://ncbi.nlm.nih.gov/pubmed/28903444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15735
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki